US 12,251,371 B2
Deuterated or partially deuterated N,N-dimethyltryptamine compounds
Peter Rands, London (GB); Ellen James, London (GB); Tiffanie Benway, London (GB); Zelah Joel, London (GB); and Marie Layzell, London (GB)
Assigned to Cybin UK Ltd., London (GB)
Filed by CYBIN UK LTD, London (GB)
Filed on Feb. 2, 2023, as Appl. No. 18/163,388.
Application 18/163,388 is a continuation of application No. 17/680,411, filed on Feb. 25, 2022, granted, now 11,660,289.
Application 17/680,411 is a continuation of application No. PCT/EP2021/082227, filed on Nov. 18, 2021.
Claims priority of application No. 2018955 (GB), filed on Dec. 1, 2020; application No. 2103981 (GB), filed on Mar. 22, 2021; application No. PCT/EP2021/060750 (WO), filed on Apr. 23, 2021; application No. 3118556 (CA), filed on May 13, 2021; application No. 2106881 (GB), filed on May 13, 2021; and application No. PCT/EP2021/062794 (WO), filed on May 13, 2021.
Prior Publication US 2023/0181530 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/16 (2006.01); A61K 31/40 (2006.01); A61K 31/4045 (2006.01)
CPC A61K 31/4045 (2013.01) [C07D 209/16 (2013.01)] 19 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
n is 1, and wherein R1 is 5-methoxy or 5-bromo;
R2 is CD3;
R3 is CD3 or H;
and
each yH is deuterium;
or a pharmaceutically acceptable salt thereof.